Beam Therapeutics Inc. — Q3 2020 Form 10-Q Summary
Business context and reporting period
Beam Therapeutics is a research-stage biotechnology company developing precision genetic medicines based on proprietary base-editing technology. Its programs were preclinical as of September 30, 2020, with pipelines focused on ex vivo electroporation, lipid nanoparticles and AAV delivery. This unaudited Form 10-Q covers the three and nine months ended September 30, 2020, with comparisons to the same periods in 2019.
Financial performance and liquidity
| Metric | Q3 2020 | Q3 2019 | 9M 2020 | 9M 2019 |
|---|---|---|---|---|
| License revenue | $0.006 million | $0.006 million | $0.018 million | $0.012 million |
| Research and development expense | $29.825 million | $12.543 million | $70.728 million | $34.402 million |
| General and administrative expense | $7.502 million | $5.487 million | $21.251 million | $14.393 million |
| Loss from operations | $(37.321) million | $(18.024) million | $(91.961) million | $(48.783) million |
| Net loss | $(34.452) million | $(19.005) million | $(99.128) million | $(50.476) million |
| Net loss per share | $(0.69) | $(3.31) | $(2.31) | $(9.58) |
| Operating cash flow | Not provided for the quarter | Not provided for the quarter | $(71.443) million | $(54.203) million |
Revenue remained immaterial and the filing does not provide a meaningful revenue-based margin. Nine-month operating expenses increased substantially as Beam expanded research activities, personnel, outsourced research and manufacturing services, licensing activity and facilities.
- Cash and cash equivalents were $137.903 million at September 30, 2020, compared with $37.221 million at December 31, 2019.
- Marketable securities were $64.317 million, producing cash, cash equivalents and marketable securities of $202.220 million.
- Total assets were $278.273 million and total liabilities were $78.202 million.
- Lease liabilities totaled $28.150 million and equipment financing liabilities totaled $6.181 million, including current and long-term portions.
- The company had an accumulated deficit of $302.172 million and expects continuing operating losses and negative operating cash flow.
- Cash, cash equivalents and restricted cash increased by $102.190 million during the first nine months, primarily because of the February 2020 IPO.
Material changes versus the prior comparable periods
- Q3 research and development expense increased $17.282 million, or approximately 138%, to $29.825 million. The increase reflected higher laboratory and outsourced services, a $5.0 million Prime Medicine stock-based license expense, increased personnel and facility costs, and higher stock-based compensation.
- Nine-month research and development expense increased $36.326 million, or approximately 106%, to $70.728 million. The filing identifies higher outsourced research, Bio Palette and Prime Medicine license expenses, personnel, facilities and stock compensation as key drivers.
- Q3 general and administrative expense increased $2.015 million to $7.502 million; nine-month expense increased $6.858 million to $21.251 million, driven principally by public-company insurance, intellectual property and personnel costs.
- Nine-month net loss increased $48.652 million to $99.128 million, reflecting the expanded operating base and an $8.700 million increase in the fair value of success-payment liabilities.
- The February 2020 IPO generated approximately $188.3 million of net proceeds and converted all outstanding redeemable convertible preferred stock into common stock.
- Common shares outstanding increased to 50.439 million at September 30, 2020 from 7.326 million at December 31, 2019, primarily due to the IPO and preferred-stock conversion.
Guidance, outlook, risks and unusual items
- Management expects operating losses and negative operating cash flow for the foreseeable future and does not expect product-sale revenue in the near term.
- The company stated that cash, cash equivalents and marketable securities at September 30, 2020, together with October financing proceeds, should fund operations for at least the next twelve months. It also expects to require additional financing.
- In October 2020, after the reporting date, Beam sold 5.750 million common shares at $23.50 per share for approximately $126.6 million of net proceeds.
- Beam expects to file an IND for BEAM-101 during the second half of 2021, nominate its first liver-program development candidate in 2021 and obtain initial non-human-primate LNP data in early 2021. These are forward-looking expectations, not achieved milestones.
- In August 2020, Beam entered into a lease for a planned 100,000-square-foot cGMP manufacturing facility in North Carolina. The company expects to invest up to $83.0 million over five years and anticipates the facility will be operational by the first quarter of 2023. Estimated minimum undiscounted lease payments were $63.9 million, subject to adjustment.
- COVID-19 had not significantly affected operations during the first nine months, but remote work, restricted facility access and additional safety protocols could increase costs or delay preclinical development.
- Success-payment liabilities to Harvard and the Broad Institute totaled $16.5 million at September 30, 2020 and are remeasured each reporting period. No success payments were due or paid as of that date.
- The company recognized a $5.0 million research and development expense for its obligation to issue shares to Prime Medicine and issued 200,307 shares in October 2020 in exchange for 5.0 million Prime Medicine shares.
- A pending USPTO interference proceeding involving CRISPR-related patent rights could affect Beam’s ability to license or commercialize certain technologies. The filing states that the proceeding had moved to the priority phase and could take approximately a year or longer.
- No material legal proceedings were reported, and management concluded disclosure controls were effective as of September 30, 2020.
Important facts for investors to verify
- Whether the October 2020 financing and post-period share issuances are reflected consistently in subsequent capitalization tables and dilution analyses.
- The company’s cash runway relative to its increasing research spending, planned clinical development and manufacturing-facility commitments.
- Progress toward the stated BEAM-101 IND filing, liver-program candidate nomination and LNP non-human-primate data.
- The status and potential financial or commercial impact of the CRISPR patent interference and other intellectual-property disputes.
- Future changes in Harvard and Broad Institute success-payment liabilities, including the effect of Beam’s share price and valuation assumptions.
- Potential delays, additional costs or operational effects from COVID-19 and construction of the North Carolina manufacturing facility.